Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.54 |
| ▸ | CTSL | P07711 | 14/20 | 0.54 |
| ▸ | CTSB | P07858 | 5/20 | 0.39 |
| ▸ | CTSK | P43235 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366946 | 0.93 | CTSS (0.53) | CTSSCTSLCTSBCTSK | |
| SCHEMBL14383667 | 0.93 | CTSS (0.53) | CTSSCTSLCTSBCTSK | |
| SCHEMBL14383668 | 0.90 | CTSS (0.46) | CTSSCTSLCTSBCTSK | |
| SCHEMBL5368517 | 0.90 | CTSS (0.46) | CTSSCTSLCTSBCTSK | |
| SCHEMBL5360338 | 0.89 | CTSS (0.48) | CTSSCTSL | |
| SCHEMBL5372284 | 0.89 | CTSS (0.48) | CTSSCTSL | |
| SCHEMBL14383680 | 0.89 | CTSS (0.48) | CTSSCTSL | |
| SCHEMBL5362268 | 0.87 | CTSS (0.56) | CTSSCTSL | |
| SCHEMBL5363194 | 0.87 | CTSS (0.41) | CTSSCTSL | |
| SCHEMBL14383676 | 0.87 | CTSS (0.41) | CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH HOLDINGS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-6812227-B2 | SULFUR COMPOUNDS SUCH AS 2-((4-BUT-2-YNYLOXY-BENZENESULFONYL)-METHYL-AMINO)-N-HYDROXY-3-METHYL -BUTYRAMIDE, USED AS TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) INHIBITORS, FOR PROPHYLAXIS OF RHEUMATIC DISEASES, SEPSIS OR INFLAMMATION | WYETH HOLDINGS CORPORATION | 2004-11-02 | — | — | US | disclosed |
| EP-1144368-B1 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6716833-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE AND DEGENERATIVE CARTILAGE LOSS. | WYETH HOLDINGS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | disclosed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | disclosed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | CTSS 143/4885CTSL 70/4885CTSB 121/4885 |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CTSS 1/4885CTSL 8/4885CTSB 3/4885 |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | CTSS 143/4885CTSL 70/4885CTSB 121/4885 |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | CTSS 143/4885CTSL 70/4885CTSB 121/4885 |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, MMP12 | CTSS 108/4885CTSL 47/4885CTSB 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.